Kornimate/medical-research-clean huggingface dataset:
the connect study: neurological complications of ttp

Conditions: Thrombotic Thrombocytopenic Purpura

Summary: thrombotic thrombocytopenic purpura (ttp) is a rare condition, which has a very high risk of death if not recognised and given immediate treatment. ttp is caused by a very low level of an enzyme in the body, called adamts13. a lack of adamts13 causes multiple small clots to form around the body which can disrupt the blood flow to important organs. although survival has improved significantly, it is now being recognised that patients with ttp may suffer with longer term complications as a result of their condition; literature from the usa reports higher rates of major depression and also poor memory and reduced concentration in patients with ttp. the investigators aim to improve the understanding of the long-term complications and review, for the first time, forward-looking data at multiple time points in patients with ttp in the uk. both patients with a new diagnosis and patients with a known diagnosis of ttp identified in nhs hospitals will be included, over a minimum duration of 2 years. this will be a questionnaire based study with both doctor led and participant led questionnaires at pre-determined points in time. by improving the understanding and comparing symptoms to that of the general population, the investigators hope to improve the support and tailor the treatments which can be offered to patients with ttp.


Eligibility criteria:
inclusion criteria: 1.acute episode ttp: * adult male or female patient ≥18 years of age at the time of signing the consent form, with a confirmed diagnosis of ttp (initial or relapse) based on adamts13 \<10% 2. known diagnosis of ttp: * adult male or female patient ≥ 18 years of age at time of signing the consent form, with a historical confirmed diagnosis of ttp (based on adamts13 at initial presentation \<10%) 3. healthy control: * non-blood relative / friend / carer of patients under the care of haematology clinics at the royal liverpool university hospital or other participating centres. exclusion criteria: 1. acute episode of ttp: * participants less than 18 years old at the time of signing the consent form * patient with adamts13 greater than 10% * patient with cancer or transplant associated maha will not be included * patient (or nok, where patient does not have capacity) not wishing to consent to trial 2. known diagnosis of ttp: * participants less than 18 years old at the time of signing the consent form * patient with adamts13 greater than 10% * patient with cancer or transplant associated maha will not be included * patient (or nok, where patient does not have capacity) not wishing to consent to trial 3. for healthy control: * participants less than 18 years old at the time of signing the consent form * participant not wishing to consent to trial * any personal or family history of thrombotic microangiopathy
seroprevalence of kaposi's sarcoma herpes virus in the united states

Conditions: Kaposi's Sarcoma; Herpesviridae Infection

Summary: this study will investigate patterns of kaposi's sarcoma herpes virus (kshv) in the united states and its potential impact on the u.s. population. kshv is a newly discovered virus that is strongly associated with kaposi's sarcoma and primary effusion lymphoma. the high prevalence of ks and kshv among hiv-infected homosexual men suggests sexual contact as a primary mode of transmission. reports of non-sexual transmission in parts of africa and the mediterranean where kaposi's sarcoma is endemic, and the identification of viral dna in saliva and other bodily fluids, however, indicate the virus is also transmitted non-sexually. this study will: * compare the prevalence of kshv among different demographic groups in the united states * examine the association between kshv and high risk behaviors such as drug use (marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of sexual partners), and medical risk factors (herpes simplex virus ii, hepatitis b and hepatitis c) * estimate the prevalence of kshv in the united states. data and blood samples for the study will be taken from the nhanes iii survey. nhanes is a program of periodic surveys conducted by the centers for disease control and prevention's national center for health statistics. the survey is designed to provide national estimates of health status for the united states non-institutionalized civilian population by means of household interviews, standardized physical examinations, and blood sample collection and testing. nhanes iii-the seventh in a series of national examination studies-was conducted from 1988 to 1994. this study will use the hanes data to identify risks associated with a kshv-positive blood test in the survey population. the study plans to include all 19,754 participants (67% of the 29,314 participants originally examined) for whom blood samples were collected and remain available.

kaposi sarcoma herpesvirus (kshv) is the viral cause of kaposi sarcoma. although infection with this virus appears to be uncommon in the united states, the prevalence in the general population in uncertain, and routes for transmission are poorly characterized. this study makes use of questionnaire data and serum specimens obtained in the third national health and nutrition survey (nhanes iii). sera from 18,168 individuals in this study were tested for antibodies to the kshv proteins k8.1 and lana. we will use these measurements to estimate kshv seroprevalence for the overall u.s. general population and for demographic subgroups. to characterize potential transmission routes, we will also examine whether kshv seroprevalence is related to sexual activity and exposures to blood, as indicated by responses to questionnaire items and previous nhanes iii measurements of markers of relevant viral infections.

Eligibility criteria:
* no specific eligibility criteria was provided for this protocol.

Keywords: human herpesvirus b nhanes epidemiology population-based study kaposi's sarcoma herpes virus
preventive therapy of white spot lesions using different remineralizing agents in children from 3 to 12 years old

Conditions: White Spot Lesion

Summary: compare by clinical observation, photographs and fluorescence the efficacy of sodium fluoride, silanofluoride and thiefenfluoride in treating white spots.

this in vivo study will be a randomized experimental clinical trial to be carried out in the department of pediatric dentistry of the international university of catalonia. patients between the ages of 3 and 12, who attend the dental university clinic of the international university of catalonia, will be part of the study. parents or legal guardians will be informed of the treatment procedure with a patient information sheet and informed consent will be given. once signed, the patient will be assigned to one of the 3 study groups. accepting an alpha risk of 5% and with a power of 80% in a bilateral contrast, 15 subjects in each group are required to detect a minimum difference of 4 points between two groups, assuming that there are 3 groups and a standard deviation of 4.9. a follow- up loss rate of 10% has been estimated. the total number of children will be 45 by 15 for each group. in order to analyze the degree of agreement of one examiner, 15 children will be evaluated twice, with a separation of one month.

Eligibility criteria:
inclusion criteria: * patients born between 2008 and 2017 of both sexes * patients with the active white spot lesions on vesicular and buccal surfaces of the incisors and molars of different sizes and with or without sensitivity to external stimuli * patients with white spot lesions that correspond to codifications of 0 to 2 of the icdas criteria. exclusion criteria: * patients with mental disabilities or systemic diseases * patients with previously restored teeth * patients with clinical symptoms of irreversible pulpitis, allergy to fluoride and copper
pre-market verification of portable x ray machines for lung diseases and orthopedic limb lesions

Conditions: X-rays; Effects; Chest--Diseases; Orthopedic Disorder

Summary: the clinical trial is to evaluate a portable x ray machine (model name: cvxair) for chest and extremities diagnosis, the performance of machine is comparing to the commercial stationary and portable machine both in biological structure way and disease diagnosis way by the image generated. currently sold x ray machines in market for hospital are stationary or big size portable, it is not easy for carrying to use and occupied a large space for installation and storage, beside that, cvxair is a small and light machine within 3.2kg and has extremely low dosage. it is the reason we expect to use cvxair as a convenient x ray machine with low radiation dosage for x ray image diagnosis clinically. this trial has an expected trial period in two years, the accepted patients are limited to thoracic and orthopedics patients no matter out hospital or in hospital. the accepted patients upper limitation number is 123 respectively. the selected patient will be taken x ray shot in same area and position both by cvxair and market sold machine, the images then will be interpreted by 2 qualified radiologist in different biological structure and specified diseases. then the process will be given by a suitable test score. the test result will be calculated by defined index for comparing with the market sold x ray machines, and finally we will base on the result to state the machine is equivalent or not by the market sold x ray machines.


Eligibility criteria:
inclusion criteria: * patients with lung diseases and orthopedic limb lesions. * aged 20 years or older. * after informed consent, sign the subject consent form. exclusion criteria: * patients under the age of 20 years. * pregnant women (female subjects of childbearing potential, undergo pregnancy testing prior to irradiation to exclude the risk of pregnancy). * other individuals deemed unsuitable for inclusion in the clinical trial upon physician assessment.

Keywords: portable x ray machine extremities telemedicie
determination of predictive genetic markers of toxicity after hypofractionated radiotherapy in breast cancer patients post-conservative surgery

Conditions: Breast Cancer

Summary: the single shot partial breast irradiation (sspbi) trial was designed as a prospective phase ii "single-arm study". the use of a single dose tumor bed is expected to be very effective in terms of tumor control, but it could increase the incidence of radiation induced erythema. therefore, the investigators assumed that a decreased dna repair capability, as well as a reduced detoxification of the damage caused by oxidative stress could explain the increased acute toxicity, i.e. a higher incidence of erythema after a single dose. for this reason the investigators decided to investigate snps of genes involved in antioxidant and dna damage repair pathways such as gst, xrcc1, xrcc3 and rad51. the investigators assumed an erythema rate of 20% and 54% in patient groups at low and high risk, respectively, (groups were identified based on the absence/presence of the above polymorphisms alone or in combination), thus the minimum sample size was 56 patients with α=0.05, 2-tailed test and a power of the study of 80%.


Eligibility criteria:
inclusion criteria: * age ≥ 48 years old with a life expectancy of at least 5 years * post-menopausal status * histologically proven, non lobular, adenocarcinoma of the breast * primary tumours ≤ 3 cm * negative surgical margins (≥ 2 mm) * negative sentinel nodes or \< 4 positive axillary nodes * no extra-capsular extension * no previous radiotherapy exclusion criteria: * multicentric disease * extended intraductal component (eic \> 25%) * paget's disease * lobular adenocarcinoma * distant metastases all the above criteria allow to identify patients at low risk of local recurrence.

Keywords: toxicity after single shot partial breast irradiation (sspbi)
mechanism of action of transcranial direct current stimulation in neurofibromatosis type 1

Conditions: Neurofibromatosis 1

Summary: intellectual impairment, particularly working memory deficits are a significant cause of morbidity in children with neurofibromatosis type (nf1) with long-term implications on academic and occupational functioning. whilst significant discoveries have been made in nf1 animal models in trying to find treatments for these conditions, human translational studies have not been successful. this mechanistic experimental study will investigate the neural mechanisms underlying working memory deficits in nf1. in particular, we will investigate how individual differences in inhibitory neurotransmitter gaba relate to performance on working memory tests. further, we will investigate the use of a novel, experimental intervention called transcranial direct current stimulation (tdcs);known to modulate gaba. using a randomized, crossover design in a cohort of 30 adolescents aged 11-17 years, we will apply real or sham tdcs to the dorsolateral prefrontal cortex (dlpfc). state-of-art real time imaging techniques such as magnetic resonance spectroscopy (mrs) and task based functional mri (fmri) will be used to investigate the effect of tdcs on gaba concentration, changes in functional plasticity and working memory. we expect that results from this study will help elucidate the neural mechanisms underlying working memory deficits in people with nf1 and show biologic activity for a novel, low-cost intervention that can be used for cognitive remediation in nf1. this kind of focused mechanism trial method is a highly promising approach to understanding the complex neural system pathology in a multifactorial neurodevelopmental condition like nf1.


Eligibility criteria:
inclusion criteria: 1. meets national institute of health nf1 diagnostic criteria 2. children aged 11-17 years 3. written informed consent/assent exclusion criteria: 1. no history of intracranial pathology other than asymptomatic optic pathway glioma or other asymptomatic and untreated nf1-associated white matter lesion 2. no history of epilepsy or any major mental illness 3. no mri contraindications.
optima: an observational study of mircera (methoxy polyethylene glycol-epoetin beta) in participants with chronic kidney disease stages 3 and 4 not on dialysis

Conditions: Anemia

Summary: this prospective observational study evaluated the efficacy and safety of mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease participants on dialysis with renal anemia. participants initiated on treatment with mircera according to the summary of product characteristics and standard clinical practice were followed for 10 months.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * participants with chronic kidney disease (ckd) not on dialysis with renal anemia (ckd stages 3 \& 4) * initiated on mircera treatment (participants may have received mircera treatment for up to 3 months before study enrollment) * life expectancy \> 10 months exclusion criteria: * malignant disease * significant or acute bleeding * poorly controlled hypertension * blood transfusion during the previous 2 months * hypersensitivity to mircera or any of its excipients
investigate the safety/tolerability and efficacy of bilastine 20mg in korean patients with seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: the objective of the study was to determine the efficacy and tolerability of 20 mg of bilastine, compared to desloratadine and placebo for the treatment of seasonal allergic rhinitis.


Eligibility criteria:
inclusion criteria: * the study disease was diagnosed on the basis of clinical criteria: nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering. * patients with history of seasonal allergic rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their informed consent, attended the required visits scheduled and also underwent a complete medical examination.. exclusion criteria: * patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or hypersensitivity that could be harmed. * patients were not allowed to take forbidden medications or not comply the study requirements. * patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded. * pregnant or breast-feeding women were also excluded. * women of childbearing potential had a pregnancy test done
measurement of tissue oxygen saturation in chronic critical limb ischemia

Conditions: Peripheral Arterial Disease

Summary: near-infrared spectroscopy can be used to determine the relative oxygen saturation in tissues up to 2cm below the skin. it has been investigated, with success, in cerebral, gastrointestinal, and muscle tissue, and shows promise in numerous indications involving tissue ischemia. in the current study, we propose to examine one hundred patients requiring either bypass or angioplasty due to chronic critical limb ischemia resulting from peripheral arterial disease. we intend to challenge patients before and after the intervention, using either an inflated blood pressure cuff or toe raises, to determine if oxygen saturation recovery time in the affected limb is correlated with symptom resolution (i.e. treatment success). near-infrared spectroscopy will be performed using the odissey tissue oximeter developed by vioptix, inc. the proposed study will take approximately one year to complete enrolment, and has a follow-up period of 6 months post-intervention. study hypothesis: knowledge of tissue oxygen saturation enhances clinical decision making in patients with chronic critical limb ischemia.


Eligibility criteria:
inclusion criteria: * \>= 18 years old * pad * chronic critical limb ischemia * requiring surgical intervention * able to give informed consent exclusion criteria: * emergent/urgent requirement for surgical intervention * requiring surgical intervention due to acute traumatic injury

Keywords: tissue oxygen saturation peripheral arterial disease critical limb ischemia near-infrared spectroscopy
long term effects of raloxifene treatment on bone quality

Conditions: Osteoporosis, Post-Menopausal

Summary: this is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the continuing outcomes relevant to evista study.


Eligibility criteria:
inclusion criteria: * have completed the core protocol within 3 months (90 days) prior to study entry and enrollment. * have taken randomized study material for at least 7 years since enrollment in the more protocol. if the patient opted not to receive randomized study material for a period of 6 months at any point during either the more or core protocol, this period must have occurred in its entirety before visit 3 of the core protocol. * overall, were at least 75% compliant with randomized study material during the more and core protocols. exclusion criteria: * have an allergy or other intolerance to tetracycline hydrochloride that would preclude its administration in conjunction with the bone biopsy procedures. if the patient is not allergic to all tetracyclines, then this exclusion may be waived by the sponsor and a different tetracycline to which the patient is not allergic may be used. * have undergone two previous transiliac bone biopsies (one in each iliac crest). patients with one previous transiliac bone biopsy are eligible provided that the new sample is obtained from the contralateral iliac crest. * in the opinion of the investigator, have any medical or anatomical condition that potentially could put the patient at additional risk of an adverse event due to the procedure (for example, coagulation abnormality, extreme obesity, etc.). * have a history of bone metabolic diseases, paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption. * have a history of malignant neoplasms in the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. if malignant neoplasm was ever diagnosed, patient must presently be free of disease.
the effect of sleep quality on mental and physical health

Conditions: Mental Health Issue; Physical Stress

Summary: this study aimed to explore the relationship between sleep quality and its impact on mental and physical health, particularly in the context of stress. a mixed methods approach will be used including: a pre-test questionnaire and physiological measurements that depend on scales for measuring to assess sleep patterns: dass21, fatigue assessment scale, epworth sleeping scale, and sf-12 health survey scoring. all of that will highlight the importance of addressing sleep quality as a crucial factor in promoting overall well-being.

this study aims to explore the relationship between sleep quality and its impact on mental and physical health, particularly in the context of stress. a mixed methods approach will be used including: a pre-test questionnaire and physiological measurements that depend on scales for measuring to assess sleep patterns: dass21, fatigue assessment scale, epworth sleeping scale, and sf-12 health survey scoring. all of that will highlight the importance of addressing sleep quality as a key factor in promoting overall well-being. in conclusion, understanding the intricate relationship between sleep quality, stress, and mental and physical health is vital for promoting holistic well-being, developing effective interventions, and improving health outcomes at individual, community, and societal levels. by recognizing the significance of this research, we can work towards creating a healthier and more resilient population.

Eligibility criteria:
inclusion criteria: -university students between the ages of 18 and 35. exclusion criteria: * people with diseases and conditions can significantly affect sleep quality, cause fatigue, and impact mental and physical health along with relevant medications that might exacerbate these issues: diseases and conditions: * restless legs syndrome (rls) * bipolar disorder * fibromyalgia: * parkinson's disease * multiple sclerosis (ms) * thyroid disorders medication: * sleep aids * antidepressants * diuretics * antihistamines * hormonal medications * blood pressure medications

Keywords: sleep and mental health stress-sleep connection mental health and sleep sleep disorders and health impact sleep and stress effects sleep impact on physical health sleep quality